We do not generally collect personal information through our website. However, when you contact emails within the finchtherapeutics.com domain, we may collect personal information, such as your e-mail address, name, home or work address and/or telephone number, if provided voluntarily. Any such personal information you voluntarily provide to us may be used to respond to requests and questions you may have.
We use Google Analytics to analyze the use and performance of our website. The information we collect does not contain personally identifiable data. We use the anonymous information we collect through Google, for example, pages visited, length of user session, and referring website, to maintain and continually improve the information provided on our website.
Links to Other Websites
Our website may contain links to other third-party websites. We do not control the privacy policies or practices of these third-party websites. We are not responsible for the content or practices of any linked third-party websites. These links are provided solely for the convenience of our visitors.
We use reasonable security measures to store and maintain personally identifying information to protect it from loss, misuse, alteration or destruction by any unauthorized party while it is under our control.
Questions or Concerns
Last revised: January 8, 2021
Human-First Discovery is a trademark of Finch Therapeutics Group, Inc.
Expanded Access Policy
At Finch, we are dedicated to harnessing the microbiome to transform lives and we are working with urgency to advance the development of novel microbiome therapeutics.
At this time, Finch does not offer an expanded access program, also known as compassionate use, and we do not accept expanded access requests. Currently, Finch does not supply its investigational, or experimental, microbiome therapeutics outside of formal clinical trials designed to evaluate the safety and efficacy of microbiome therapeutics for different conditions and patient populations.
Our expanded access policy is grounded in our commitment to patient safety and our commitment to generating, as quickly as we can, the robust clinical trial data required to adequately assess safety and efficacy and potentially support the future regulatory approval and widespread availability of our investigational therapeutics for the conditions we are currently studying.
To learn more about our ongoing or planned clinical trials, please visit the Patients page of our website.